Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer

Murray, Nigel P; Reyes, Eduardo; Fuentealba, Cynthia; Orellana, Nelson

doi:10.7314/apjcp.2015.16.18.8387

Cited by 3 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detection of biological markers in the blood stream is not a new concept. For example, for many years the carcinoembryonic antigen (CEA), the prostate-specific antigen (PSA) or the Ca-125, among others, were used to assess the treatment response (Friedrich, 2017), defining the conduct subsequently taken, whether the clinical follow-up, maintenance of the treatment initially applied or even the search for an alternative treatment given the lack of response, which was observed with the marker increase (Murray et al, 2015;Stremitzer et al, 2015;Alexandre et al, 2012). The plasma genotyping has the potential to bring a higher number of information, not only about the decision of whether to treat or not treat, but also about how to treat or how to optimize the treatment response.…”

Section: Discussionmentioning

confidence: 99%

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective

Santos¹,

Custodio²,

Matsuo³

et al. 2018

JBES

View full text Add to dashboard Cite

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective Custo-efetividade do uso da biópsia líquida versus biópsia tecidual para detecção de câncer de pulmão de não pequenas células avançado com receptor do fator de crescimento epidérmico e mutação T790M sob a perspectiva do sistema suplementar de saúde do Brasil ABSTRACT Objective: Comparing the costs and effectiveness of plasma genotyping versus tumor genotyping for detecting the T790M mutation in advanced non-small cell lung cancer (NSCLC) with a mutation in the epidermal growth factor receptor (EGFR) and that progressed after use of an EGFR tyrosine kinase inhibitor (EGFR-TKI), from the perspective of the private healthcare system in Brazil. Methods: Patients with a post-EGFR-TKI T790M mutation are eligible for a second-line treatment with a third--generation EGFR-TKI (osimertinib). In order to estimate the costs associated with the diagnosis method for the T790M mutation, a decision tree model has been used. Resource use was estimated by a team of experts, and the direct costs were estimated based on official databases. Results: Plasma genotyping provided a R$391 reduction per patient, due to the reduced cost with complications; it prevented 40.96% of the patients from undergoing an invasive procedure and 31.91% of the patients from having any kind of complication. Conclusion: Data found support a new paradigm for treating the resistance to EGFR-TKIs, with plasma genotyping as the first diagnostic choice, what can help to define the treatment and to reduce the costs of Brazilian private healthcare system. Recebido em: 28/08/2018. Aprovado para publicação em: 27/09/2018. 263Cost effectiveness analysis of plasma genotyping for detecting T790M mutation in patients with advanced non-small cell lung cancer in Brazil Análise de custo-efetividade da genotipagem de plasma para detecção da mutação T790M em pacientes com câncer avançado de pulmão de não pequenas células no Brasil J Bras Econ Saúde 2018;10(3): 262-8Cost effectiveness analysis of plasma genotyping for detecting T790M mutation in patients with advanced non-small cell lung cancer in Brazil Análise de custo-efetividade da genotipagem de plasma para detecção da mutação T790M em pacientes com câncer avançado de pulmão de não pequenas células no Brasil J Bras Econ Saúde 2018;10(3): 262-8

show abstract

Section: Discussionmentioning

confidence: 99%

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective

Santos¹,

Custodio²,

Matsuo³

et al. 2018

JBES

View full text Add to dashboard Cite

show abstract

“…In 2015, Murray et al presented their study about PSA kinetics and bone marrow micrometastasis to define local or systemic relapse in men with biochemical failure after radical prostatectomy for prostate cancer. The authors suggested that PSA doubling time of <6 months or a total serum PSA of >2.5 ng/ml at the time of biochemical failure, the detection of bone marrow micrometastasis was significantly higher [31]. A recently published study from Chiaravalloti et al showed that the use of PSA kinetics are helpful for selecting patients for PET/CT after radical prostatectomy [32].…”

Section: Discussionmentioning

confidence: 99%

The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy

Keskin¹,

Yıldırım²,

Çanakçı³

et al. 2016

JCT

View full text Add to dashboard Cite

“…In comparison with the anterior parameters, there was no association with micrometastatic disease. The detection of bone marrow micrometastasis implies the presence of systemic relapse and such systemic treatment [172]. First line ADT treatment is with a LHRH agonist or antogonist, there is normally a decrease in the serum PSA for a period of 3–5 years.…”

Section: As a Guide To Treatment Optionsmentioning

confidence: 99%

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Murray

2018

Biol Res

View full text Add to dashboard Cite

Minimal residual disease is that not detected by conventional imaging studies and clinically the patient remains disease free. However, with time these dormant cells will awaken and disease progression occurs, resulting in clinically and radiological detectable metastatic disease. This review addresses the concept of tumor cell dissemination from the primary tumor, the micrometastatic niche and tumor cell survival and finally the clinical utility of detecting and characterizing these tumor cells in order to guide management decisions in treating patients with prostate cancer.

show abstract

Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer

Cited by 3 publications

References 17 publications

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective

Cost effectiveness analysis of plasma genotyping versus tumor genotyping in detection of advanced non-small-cell lung cancer with epidermal growth factor receptor and T790M mutation under the Brazilian private healthcare system perspective

The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Contact Info

Product

Resources

About